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license (http://creativevated nuclear factor-kappa B p65. Previously, we showed that rationally designed analogs of the
p65-binding domain of glucocorticoid-induced leucine zipper, referred to as glucocorticoid-
induced leucine zipper analogs (GAs), inhibited amyloid b–induced metabolic activity and inflam-
matory cytokines in mixed brain cell cultures. Here, we investigate the therapeutic efficacy of GA
in an Alzheimer’s disease model.
Methods: GA and control peptides were synthesized covalently as peptide amides with the cell-
penetrating agent. C57Bl/6J mice induced with lipopolysaccharide-mediated neuroinflammation
(250 mg/kg i.p/day for six days) were treated on alternate days with GA-1, GA-2, or control peptides
(25 mg/kg i.v). Brain tissues were assessed for gliosis, cytokines, and antiapoptotic factors.
Results: The brain tissues of GA-1– and GA-2–treated mice exhibited significantly reduced gliosis,
suppressed inflammatory cytokines, and elevated antiapoptotic factors.
Discussion: The antineuroinflammatory effects of GA suggest potential therapeutic application for
Alzheimer’s disease.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Neuroinflammation; NF-kB p65 blockade; Neurodegeneration; Alzheimer’s disease; Peptide therapeutics1. Background
Alzheimer’s disease (AD) is a degenerative brain dis-
ease and the most common form of dementia [1]. Patho-
logically, AD brains exhibit accumulations of amyloid b
(Ab) plaques and neurofibrillary tangles as well as
elevated inflammation-related proteins such as innate im-
mune receptors and proinflammatory cytokines. Elucida-
tions of pathogenesis suggests that both local andthor. Tel.: 317 278 9686; Fax: 317-278-3018.
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commons.org/licenses/by-nc-nd/4.0/).systemic inflammations aggravate neurotoxicity and
accelerate neurodegeneration in individuals with
increased risk for AD [2,3]. Nuclear factor-kappa B is a
critical transcription factor that regulates inflammatory re-
sponses, Ab generation, and tau deposition [4,5]. Hence,
NF-kB has long been recognized as a critical therapeutic
target for AD.
The nuclear factor-kappa B family consists of five mem-
bers (p50, c-rel, p65, RelB, and p52) that diversely combine
to form transcriptionally active dimers. In the central ner-
vous system (CNS), positive and negative regulatory mech-
anisms maintain a homeostatic balance between the
neuroprotective c-rel-containing dimers and the predomi-
nantly neurotoxic p65:p50 dimers [6,7]. In AD, age-relatedimer’s Association. This is an open access article under the CC BY-NC-ND
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activation of p65:p50 dimers. This in turn mediates
increased transcription of inflammatory mediators and of
endogenous b secretase-1, both of which enhance Ab pro-
duction [8,9]. Observation of increased proportion of
neurons with nuclear p65 in the hippocampus and cortex
around Ab plaques in postmortem AD tissues supports a
critical role for activated p65 in the process of cholinergic
degeneration [10–12]. Taken together, selective inhibition
of activated NF-kB p65 represents an attractive therapeutic
strategy for AD [9,13–15].
Glucocorticoid-induced leucine zipper (GILZ) is a tran-
scriptional regulatory protein that is constitutively expressed
in many tissues including the brain [16,17]. Functionally,
GILZ sequesters the activated p65 in the cytoplasm,
preventing its nuclear translocation and thereby
transactivation of target genes [18,19]. Structurally, GILZ
binds the transactivation domain (TAD) of p65 via a
proline glutamic acid–rich region [20–22]. The key
prolines of GILZ at interface with p65 TAD adopt an
extended polyproline type II (PPII) helical conformation
[23] and potentially interact with the side chain of phenylal-
anine residues (F534/F542) of p65 critical for its transactiva-
tion ability [24,25]. Highly represented in transient
intermolecular interfaces in human proteome, PPII helical
motifs are considered excellent epitope/s for drug
development [26,27]. We developed rationally designed
peptide mimics of the p65-binding motif of GILZ, which
form stable PPII helix in the context of p65-TAD [23]
and showed that select glucocorticoid-induced leucine
zipper analogs (GAs) inhibited Ab-induced metabolic activ-
ity and inflammatory cytokines in human mixed brain cell
cultures.
A key limitation of drug discovery in AD is that the
currently available animal models of AD do not recapitu-
late all features of the disease precluding true and meaning-
ful extrapolation of findings from models to humans
[28,29]. Although transgenic animal models emphasize
the genetic component of the disease, exogenous agent–
induced neuroinflammation models highlight the nonge-
netic processes that accelerate the degeneration in AD
[28–30]. Yet, recognizing and accommodating for these
limitations, models of neuroinflammation have been used
to test the efficacy of potential therapeutic agents that
attempt to slow the disease progression [31]. For example,
the validity of nutraceuticals such as resveratrol, glycyrrhi-
zin, and flavonoids for AD was assessed in the lipopolysac-
charide (LPS)-induced model of neuroinflammation [32–
34]. The LPS binds the co-receptor CD14 on microglial
cells, and the complex then interacts with the toll-like re-
ceptor-4. Subsequent signal transduction increases NF-kB
p65-mediated transactivation of pathological mediators,
leading to neuroinflammation and neurodegeneration
[3,31]. Here, we assessed the effects of GA in mice
following systemic LPS administration and show that
treatment with select GA suppressed neuroinflammationas indicated by reduced gliosis, decreased inflammatory
cytokines, and lessened proapoptotic transcription.2. Materials and methods
2.1. Peptides
The experimental PPII helical peptidesGA-1 andGA-2 or
control peptides (sequence [CP-1] or conformation [CP-2] or
unstructured [CP-3]). All peptides were co-synthesized with
the cell-penetrating agent transactivator of transcription of
human immunodeficiency virus (GRKKRRQRRRPQ) for
intracellular delivery as peptide amides with amino terminal
acetylation (GenScript, Piscataway, NJ) [23,35]. All peptides
were purified by semipreparative reverse-phase high
performance liquid chromatography, and the identity of the
purified peptide was confirmed by mass spectrometry.
2.2. Animals and LPS-induced neuroinflammation
LPS from Escherichia coli 026:B6, 5 10,000 EU/mg,
was purchased from Sigma (Sigma Aldrich, MO, USA).
Adult C57/6J mice were randomly divided into seven groups
of five mice/group: LPS, LPS 1 GA-1 or GA-2 or CP-1 or
CP-2 or CP-3 or transactivator of transcription of human im-
munodeficiency virus. The LPS was administered intraperi-
toneally at 250 mg/kg in 100 mL of sterile saline followed
by corn oil in the morning daily for 6 days [31,36]. The
GA or CP was administered intravenously at 25 mg/kg in
100 mL of sterile saline on alternate days. Additional
control group included mice receiving saline alone. All
animal experiments were approved by the Institutional
Animal Care and Use Committee of the Indiana University
Purdue University at Indianapolis.
2.3. Histology and immunohistochemistry
The mice were sacrificed on day 7 by intracardial perfu-
sion of 25 mL of 0.9% saline. The brain from each mouse
was removed, one half was immediately frozen, and the
other half fixed in 4% paraformaldehyde for paraffin embed-
ding. Hematoxylin- and eosin-stained sections were as-
sessed for inflammation.
Serial 5-m-thick coronal sections of each brain specimen
were immunostained for markers of microglial cells, astro-
cytes, and NF-kB p65. Briefly, after deparaffinization and
hydration, sections were subjected to antigen retrieval bymi-
crowave incubation in 10 mM sodium citrate buffer (pH 6.0)
followed by sequential incubation in 30% hydrogen
peroxide and blocking buffer (Enzo biosciences, Farming-
dale, NY) to reduce nonspecific binding. The sections
were then stained with the following primary monoclonal
antibodies from EMD Millipore Corporation, Temecula,
CA, USA: anti-Iba-1 (AIF1 clone: Cat. # MABN92) or
anti-glial fibrillary acidic protein (GFAP) clone GA5 (Cat.
# MAB3402, Millipore) or anti-CD11b (Cat. #.
MABF513) clone M1/70 or anti-NF-kB p65 subunit clone
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GFAP, the detection was performed with the use of immuno-
histochemistry select immunoperoxidase secondary detec-
tion system (Millipore). The peroxidase-conjugated
streptavidin-biotin method was used, and brown staining
was considered positive. For dual staining of CD11b and
NF-kB p65, detection was achieved using the MULTIVIEW
(mouse-HRP/rabbit-AP) IHC kit (Catalog #: ADI-950-100,
ENZO Life Sciences). For each marker, to confirm the spec-
ificity of the antibodies, a separate set of sections from each
group were incubated with secondary antibodies alone.2.4. Quantitative analysis of staining intensity
Images of the IHC-stained sections were captured using
the NIKON Multiphoton microscope with attached DS Ri2
camera. Five areas encompassing the hippocampus of each
brain section were analyzed using the ImageJ Software
[37]. The number and the relative optical density of Iba11
andGFAP1 glial cells were determined using themultipoint
tool and the IHC-tool box. Training for brown/red color was
performed before measurement to define the threshold for
positive selection. Regions of interest encompassing the hip-
pocampus were identified in each section, and the corre-
sponding images were quantified using integrated optical
density, normalized to the background optical density. Mea-
surement of pixel intensitywas restricted to the 3,30-diamino-
benzidine- or alkaline phosphatase-stained pixels of cells
within defined circularity. Five consecutive coronal sections
were assessed for each mouse.2.5. Enzyme-linked immunosorbent assay for cytokines
Frozen brain tissuewas homogenized in RIPA lysis buffer
(50 mmol/LTris–HCl, pH 6.8, 150 mmol/L NaCl, 5 mmol/L
EDTA, 0.5% sodium deoxycholate, 0.5% NP-40) supple-
mented with a cocktail containing protease and phosphatase
inhibitors (Chemicon, Millipore) on ice and then centrifuged
at 16,000 ! g for 30 min [14,15,36]. The supernatant was
stored at 280C until further analysis. For each sample,
10 mL of extracted protein was used for measuring the
cytokines interleukin (IL)-6, tumor necrosis factor-alpha,
interferon-gamma, IL-10, and transformation growth fac-
tor-b using specific OptEIA kits (BD Biosciences, CA).
2.5.1. NF-kB assay
Brain homogenates processed as mentioned previously
were assessed by the Cell Signaling Technology PathScan
Phospho-NF-kB p65 (Ser536) Sandwich ELISA kit
following manufacturer’s protocol (Cell Signaling Technol-
ogy, Boston, MA). Briefly, 40 mL of the extracted protein
mixed with 60 ml of the sample diluent was added to phos-
phor p65 (Ser536) mouse mAb–coated microwells and incu-
bated overnight at 4C. After washing, the captured
phospho-NF-kB p65 protein was detected by incubating
with horseradish peroxidase–conjugated NF-kB p65 rabbitmAb followed by color development with 3,30,5,50-tetrame-
thylbenzidine substrate. Absorbance at 450 nM was
measured using a microplate reader (Model 680; Bio-Rad
Laboratories, CA, USA). Nuclear extracts of Raji cells
served as the positive control.
2.6. Real-time polymerase chain reaction
The total cellular RNAwas isolated from each brain tis-
sue using Qiagen kit (Invitrogen, Carlsbad, CA) and reverse
transcribed using iScript cDNA synthesis kit (Bio-Rad, CA).
Equal amount of cDNA measured by the NanoDrop
(Thermo Fisher Scientific, Waltham, USA) was used for
amplification of IL-1b, IL-12, CD14, B-cell lymphoma-ex-
tra large (Bcl-xL), and B-cell lymphoma 2 (Bcl-2). Real-
time polymerase chain reaction was performed using
SYBR green/ROX quantitative polymerase chain reaction
master mix (SA Biosciences, Frederick, MD) on the ABI
Prism 7000 sequence detection system (Applied
Biosystems, Foster City, California, USA) as described
[23]. The primers used were as follows: F-bActin:
50TCATGAAGTGTGACGTTGACATCCGTA30; R-bActin:
50CCTAGAAGCATT TGCGCTGCACGAT GG30 (102 bp);
F-IL-1b:50AGCTGATGGCCCTAAACAGA30; R-IL-1b:50
GGTCGGAGAT TC GTAGCTGG30 (89 bp); F-CD14:50GA
GCTAGACGAGGAAAGTTGT30; R-CD14:50ACCGTA
AGCCGCTT TAA GGACAGA30 (206 bp); F-Bcl-
xL:50TGGAGTAAACTGGGGTCGCATC-30; R-Bcl-xL:50
AGCCACAGTCAT GCCC GTCAGG30 (84 bp) and F-
Bcl-2:50CTCGTCGCTACCGTCGTCACTTCG30; R-Bcl-
2:50GTGGCCCAGGT ATG ACCCAG30 (96 bp). The
gene-specific threshold cycle (Ct) was corrected by subtract-
ing the Ct for the housekeeping gene b-actin. The DCt for
experimental samples was subtracted by theDCt for the con-
trol samples (DDCt). The difference in each gene-specific
threshold between the sample from vehicle treated and
GA- or CP-treated cells was determined to obtain the relative
change in the specific mRNA. The magnitude of change in
each gene was determined by the 2-DDCt method. Each
measurement of a sample was performed in duplicates.
2.6.1. Statistical analysis
Statistical significance of the difference in the staining
intensity, cytokine concentration, and the transcript quantita-
tion between the GA-treated and the untreated or control-
peptide–treated groups was determined by one way analysis
of variance and Tuckey’s post hoc test. A value of P , .05
was considered significant.3. Results
3.1. Identification of druggable site: The interface of
p65:GILZ interaction
Structurally, p65 has dimerizing amino terminal rel ho-
mology domain, a nuclear localization sequence masked
by the IkB inhibitory complex and carboxy terminal TAD.
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tions of the TAD with co-regulators and the basal transcrip-
tion machinery. The p65-TAD is commonly divided into two
distinct regions, TAD-1521-551 consisting of 36 amino
acids and TAD-2428-520 with 92 residues [24]. While
TAD1 accounts for nearly 95% of the transactivation poten-
tial of full-length p65, TAD-2 alone is less potent mediating
about 30% activation. In particular, the conserved aromatic
residues (F534, F542), acidic residues (D531, D533), and phos-
phorylation sites (Ser529, Ser536) in p65-TAD1 have been
identified as critical for transactivation [38,39].
GILZ is a p65-TAD–binding protein that sequesters
activated p65 and inhibits transactivation of inflamma-
tory and apoptotic factors [20]. Mutational, binding and
structural studies suggested that the p65-binding region
of GILZ adopts a PPII helical conformation in the
context of critical phenylalanine in p65-TAD [7,19].
PPII helices highly represented at interfaces of
transient protein interactions in human proteome and
often behave as adaptable gloves in obtaining the
correct binding orientation. The specificity of PPII
interaction is determined by residues of the interacting
partner. PPII interface mimics constitute excellent drug
templates [26,27,40]. GAs are rationally designed
peptides with residue substitutions in the p65-binding
motif of GILZ with increased propensity to form stabilityFig. 1. The docked complex of GA-1 with human p65-TAD. Representative mol
proline in each GA and the critical phenylalanine are highlighted in red and blu
the interface is shown. (C and D) show Ramachandran plot of GA-1 (C) or GA-
of PPII helical conformation. Abbreviations: TAD, transactivation domain; GA, gof PPII helical conformation in the context of p65-TAD
(Fig. 1). Screening 40 GAs, we selected two analogs
referred to as GA-1 and GA-2 that exhibit good PPII po-
tential, near-native docking with p65-TAD, acceptable
binding strength for transient interactions, and inhibitory
potential in cellular assays for evaluating the in-vivo
therapeutic efficacy. In silico predictions suggest that
the predominant proteolytic products of GA-1 or GA-2
are to the right of the cell-penetrating carrier, suggesting
that the GA is potentially delivered intracellularly as
intact cargo to bind the activated p65 in the cytosol.3.2. GA prevented LPS-induced microglial and astrocyte
activation in the hippocampus
It has been well documented that peripherally injected
LPS induce a variety of central effects. Multiple injections
of LPS increase the number of F4/801, CD11b1, or Iba1-
1 cells and induce morphological changes characteristic
of activated microglia in the CNS [31,36,41,42]. We
observed that the mice induced neuroinflammation and
treated with GA-1 or GA-2 exhibited reduced Iba11 micro-
glial cells and GFAP1 astroglial cells in the hippocampus as
compared with that in the hippocampus of mice treated with
CP or left untreated (Figs. 2 and 3). Furthermore, we also
observed that the number of CD11b1 p651 glial cellsecular model of p65-TAD docked with GA-1 (A) or GA-2 (B). The critical
e, respectively. The distance between the Cb atoms of the two residues in
2 (D) with the phi and psi angles of the critical proline (in red) suggestive
lucocorticoid induced leucine zipper analog; PPII, polyproline type II.
Fig. 2. Representative images of degrees of microgliosis in mouse hippocampus. (A) shows representative IHC section stained for Iba 1 microglia in hippo-
campus of representative mouse treated with the indicated compound (B) shows the mean optical density of the 3,30-DAB-positive cells depicting microglia in
groups of vehicle or indicated compound-treated mice. Abbreviations: CP, control peptide; GA, glucocorticoid induced leucine zipper analog; DAB, diamino-
benzidine; IHC, immunohistochemistry. *P , .05.
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pocampus of GA-1– or GA-2–treated mice as compared
with that in untreated or CP-treated mice (Fig. 4).3.3. GA suppresses LPS-induced accumulation of
inflammatory proteins in the hippocampus
We next investigated the brain tissues for cytokines
known to be critical for microglial activation and gliosis in
LPS-induced neuroinflammation [31,36,42]. Brain tissuehomogenates of GA-1– or GA-2–treated mice exhibited
reduced IL-6 (18.7 6 2 pg/mL and 19.6 6 0.84 pg/mL,
respectively) as compared with the homogenates of un-
treated (32.4 6 4.7 pg/mL) or CP-treated mice (Fig. 5A).
Similarly, brain homogenates of GA-1– or GA-2–treated
mice exhibited reduced tumor necrosis factor-alpha
(1500.1 6 476 pg/mL and 1199.2 6 356.4 pg/mL respec-
tively) as compared with the untreated (2287.7 6 473 pg/
mL) or the CP-treated mice (Fig. 5B). The concentration
of interferon-gamma was also significantly lower in the
Fig. 3. Representative images of degrees of astrogliosis in mouse hippocampus. (A) shows representative IHC section stained for GFAP1 microglia in hip-
pocampus of representative mouse treated with the indicated compound (B) shows the mean optical density of the 3,30-diaminobenzidine-positive cells depict-
ing astrocytes in groups of vehicle or indicated compound-treated mice. Abbreviations: CP, control peptide; GA, glucocorticoid induced leucine zipper analog;
GFAP, glial fibrillary acidic protein; DAB, diaminobenzidine; IHC, immunohistochemistry. *P , .05.
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(3125.1 6 815 pg/mL) treated mice as compared with the
untreated (4788.2 6 2069.1 pg/mL) mice (Fig. 5C). The
concentration of IL-12 was also significantly lower in brainFig. 4. Representative images of NF-kB p651 microglia in mouse hippocampus.
(brown) microglia (B) shows themean optical density of the 3,30-DAB-positive cell
mice. Abbreviations: NF-kB, nuclear factor-kappa B; CP, control peptide; GA, glu
immunohistochemistry.homogenates of GA-1– or GA-2–treated mice (92.0 6 9.3
pg/mL, 101.3 6 15.9 pg/mL) than that in the brain tissues
of untreated mice (132.9 6 17 pg/mL) or CP-treated mice
(Fig. 5D).(A) Shows representative IHC section stained for CD11b1 (red) and p651
s depicting p65microglia in groups of vehicle or indicated compound-treated
cocorticoid induced leucine zipper analogs; DAB, diaminobenzidine; IHC,
Fig. 5. Effect of GA treatment on cytokines in brain tissues in LPS-induced neuroinflammation: Adult C57Bl/6 mice were subjected to LPS-induced neuro-
inflammation and treated with the indicated GA or control peptides as described inmaterials andmethods. Protein extracts of brain tissues harvested at the end of
experiment was assessed for indicated proinflammatory cytokines (A) IL-6, (B) TNF-a, (C) IFN-g, (D) IL-12 and (E) activated p65 NF-kB subunit. Values are
average/-S.D. *P, .05 as compared with vehicle-treatedmice,@P, .05 as comparedwith CP-1 or CP-2 or CP-3–treatedmice. Abbreviations: NF-kB, nuclear
factor-kappa B; GILZ, glucocorticoid-induced leucine zipper; LPS, lipopolysaccharide; GA, glucocorticoid induced leucine zipper analog; CP, control peptide;
IL, interleukin; TNF-a, tumor necrosis factor-alpha; IFN-g, Interferon-gamma.
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LPS-induced neuroinflammation
Because LPS is a potent stimulator of NF-kB and GA are
designed to sequester activated p65, we measured the acti-
vated p65 in the brain homogenates using specific ELISA
kits.We observed that the absorbance suggestive of activated
p65 was significantly lower in the brain protein extract from
mice treated with GA-1 (0.098 6 0.03) or GA-2 (0.12 6
0.07) than that of extract from mice left untreated (0.29 6
0.08) or treated with CP-3 (0.23 6 0.09) (Fig. 5E).3.5. GA treatment inhibited LPS-induced suppression of
antiapoptotic factors
To investigate the effects of GA on neurotoxicity, we
determined the expressions of antiapoptotic factors Bcl-xL
and Bcl-2 by real-time polymerase chain reaction. In addi-
tion, inhibition of LPS-induced cytokine secretion correlated
with the decreased levels of steady-state mRNA for IL-1b in
the brain tissues of in GA-1– or GA-2–treated mice (Fig. 6A
and B). We observed that the relative expression of CD14
mRNA was significantly lower in brain tissues of GA-1
Fig. 6. Effect of GA treatment on apoptosis-related molecules in brain tissues of LPS-induced neuroinflammation: Groups of adult C57Bl/6 mice were sub-
jected to LPS-induced neuroinflammation and treated with the indicated GA or control peptides as described in materials and methods. Equal quantity of
cDNA isolated from brain tissues of mice treated with GA or CP were amplified for IL-1b, CD14, Bcl-xL, and Bcl-2 mRNA by quantitative PCR. The
mRNA expression in each sample was finally determined after correction with GAPDH expression. (A) Gel electrophoresis of the PCR products GAPDH
(111 bp), IL-1b (89 bp), CD14 (206 bp), Bcl-xL (84 bp), and Bcl-2 (96 bp). (B) Relative mRNA quantitation of the indicated product with respect to that
of housekeeping gene GAPDH is shown. Data are average6 SD. * P, .05 with respect to vehicle- and CP-treated group. Abbreviations: GILZ, glucocorticoid
induced leucine zipper; GA, glucocorticoid induced leucine zipper analog; LPS, lipopolysaccharide; CP, control peptide; Bcl-xL, B-cell lymphoma-extra large;
Bcl-2, B-cell lymphoma 2; PCR, polymerase chain reaction; IL, interleukin.
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the brain tissues of untreated (4.0 6 1.7) or CP (CP-1:1 6
0.3; CP-2:2.4 6 2; CP-3:1.2 6 0.1) treated mice (Fig. 6A
and C). The relative expression of Bcl-xL and Bcl-2 was
significantly higher in brain tissues of GA-1– (0.32 6 0.15
and 1.25 6 0.5, respectively) or GA-2– (0.25 6 0.4 and
1.9 6 0.9, respectively) treated mice than that in brain tis-
sues of untreated (0.11 6 0.1 and 0.22 6 0.5, respectively)
or CP (CP-1:0.06 6 0.08 and 0.36 6 0.8, CP-2: 0.13 6
0.12 and 0.45 6 0.9; CP-3: 0.13 6 0.1 and 0.44 6 0.9,
respectively) treated mice (Fig. 6A, D and E).4. Discussion
Disproportionate increase in activated NF-kB p65:p50 di-
mers is implicated in neuroinflammatory and neurotoxic re-
sponses. Meta-analysis of differentially expressed genes
showed that the increased p65 is associated with 101 of
the 168 pathways perturbed in late onset AD [43]. Systemic
inflammation and increased infiltration of mononuclear cells
with high nuclear p65 are observed in sporadic AD. Further-
more, recent elucidations suggest that the activated NF-kBincreases the transcription of proinflammatory microRNA,
which in turn downregulate many phagocytic-, synapto-
genic-, and neurotrophism-relevant genes. Elevated NF-
kB–mediated mi-RNA 125b has been observed in the
affected tissues and in the cerebrospinal fluid in AD [44].
Decoy nucleotides that inhibit NF-kb–mediated transcrip-
tional activity have been shown to inhibit Ab-triggered
release of cytochrome c, rescue expression of Bcl-xL, and
interfere with intracellular accumulation and extracellular
deposition of Ab [9,45]. Here, we report the efficacy of a
novel peptide agent that selectively inhibits activated p65
to suppress neuroinflammation.
Interfaces of protein-protein interactions are considered
excellent targets for developing peptide inhibitors [46].
Rapid proteolytic degradation and poor stability are consid-
ered significant shortcomings of peptides as drugs. Strate-
gies to overcome these inherent drawbacks and increase
in-vivo half-life include blockade of end groups as incorpo-
rated in GA. Indeed, the stability of end group–blocked Ab
peptide has been shown to be several folds higher than that of
free peptide with a half-life of over 6 h [47]. In addition,
amino-acetylation of GA could increase the lipophilicity
Fig. 7. Schematic representation of the role of NF-kB in AD pathology and the sites of action of GA: In health, a homeostatic balance between activated c-rel
containing dimers and the p65:p50 dimers plays a role in maintaining synaptic activity, neuronal plasticity, and health. In susceptible individuals, age-related
noxious stimuli activate NF-kB p65 in neuronal cells, increase transactivation of BACE-1 and consequently Ab generation. Stimulation and NF-kB p65 acti-
vation in glial cells lead to increased secretion of proinflammatory genes (such as IL-12, IL-17), proapoptotic genes and neurotoxic factors (glutamate, iNOS). A
feed forward loop ensues culminating in neurodegeneration. By selectively targeting activated p65, GA edges the disrupted balance toward the homeostatic
level. The insight shows the rationale for the efficacy of GA: an attempt to re-establish the NF-kB homeostasis and suppress excessive glial activation. Abbre-
viations: NF-kB, nuclear factor-kappa B; GA, glucocorticoid induced leucine zipper analog; Ab, amyloid b; AD, Alzheimer’s disease; BACE-1, b secretase-1;
iNOS, induced nitric oxide synthase; IL, interleukin.
M. Srinivasan et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 488-498496and improve membrane permeability, thereby enhancing de-
livery across the blood-brain barrier [48].
Traditionally, neuroinflammation in AD is considered a
reactive phenomenon secondary to damaged neurons that
provoke glial activation. However, accumulating evidence
suggest that under physiological conditions, a delicate
balance between the transient inflammatory responses
by glial cells to stress/insults and the endogenous
anti-inflammatory and neuroprotective responses in the
brain maintain the healthy status. Any perturbation of
this balance that leads to more severe and persistent neuro-
inflammatory cycle could promote neurodegeneration
culminating in clinical disease. Central or systemic LPS
administration has been shown to increase the number of
glial cells, upregulate proinflammatory cytokines in the
brain, and eventually precipitate dopaminergic neurotox-
icity [13,22,41,49]. Culture medium of LPS-stimulated mi-
croglia cells enhanced NF-kB p65 signaling and
downregulated Bcl-2 expression in neuronal cells. In
contrast, activation of NF-kB c-rel dimers has been shown
to enhance Bcl-xL expression and protect against neuronal
loss [50–52]. Our data show that in mice subjected to LPS-
induced neuroinflammation, treatment with GA-suppressed
gliosis and inflammatory cytokines as well as prevented
downregulation of Bcl-2 and Bcl-xL expression largelyby inhibiting activated p65 as indicated by the significant
reduction in phosphor-p65 in the CNS.
Although the model used here does not replicate the de-
mentia in human AD, the ability of GA to inhibit activated
NF-kB p65 and suppress gliosis and inflammatory cytokines
suggests potential therapeutic benefits for AD (Fig. 7). Inter-
estingly, GILZ shares significant sequence and structural ho-
mology with delta sleep-inducing immunoreactive peptide
originally identified by antibodies to a CNS-penetrating
hydrophilic nanopeptide [23,53]. The cross-reaction is attrib-
uted to the sequence homology between the nanopeptide and
the carboxy terminal of delta sleep-inducing immunoreactive
peptide shared by GILZ [53–55]. This suggests that the GA
designed from the carboxy terminal of GILZ will have
potential ability to reach the CNS independently. Future
studies will evaluate the efficacy of end groups blocked GA
independent of transactivator of transcription of human
immunodeficiency virus in models of AD. Given the
limitations of the Ab-centric therapies, the potential for
alternative strategies such as neuroinflammation targeting
disease-modifying therapies for AD is increasing recognized
as suggested by the rapid development of receptor for
advanced glycation end products antagonists and p38 kinase
inhibitors [56,57]. GA represents a class of agents that can
be added to this growing list of disease-modifiers for AD.
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1. Systematic review: The authors searched the literature
(using PubMed) for research articles and reviews
describing studies on therapies targeting neuroinflam-
mation and nuclear factor-kappa B for Alzheimer’s
disease. This search pointed to the increased interest
for disease-modifying therapies that slow disease
progression. There is considerable excitement for
development of novel compounds that target mecha-
nistic links between neuroinflammation, amyloid
deposition, and neurodegeneration.
2. Interpretation:We identified a unique strategy to selec-
tively suppress activated nuclear factor-kappa B p65,
the master regulator of inflammatory responses that
also is critical for Ab production. Our data show that
rationally designed analogs of the p65-binding motif
of a nuclear factor-kappa B interacting protein,
glucocorticoid induced leucine zipper suppressed
gliosis and inflammatory responses in the lipopoly-
saccharide induced neuroinflammation model of Alz-
heimer’s disease.
3. Future directions: These results are of significant
translational value and position GA as a potential
disease-modifying agent for the treatment of Alz-
heimer’s disease.References
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